The global plasmid DNA manufacturing market is projected to grow at a compound annual growth rate (CAGR) of approximately 18% from 2026 to 2034, reaching a market size of $10.8 billion. This growth is fueled by increasing demand for gene therapies, DNA vaccines, and cell-based therapies like CAR-T, alongside expanding mRNA vaccine production. Key regions leading this growth include North America, Europe, and Asia-Pacific, supported by investments in GMP-compliant manufacturing and technological advancements. Major biopharma companies are expanding capacity to meet rising clinical and commercial demand, signaling strong market momentum in genetic medicine manufacturing.

More News (CRL)

Law firm investigates Charles River Labs officers for possible breach of fiduciary duties to shareholders

Halper Sadeh LLC is investigating whether certain officers and directors of Charles River Laboratories International, Inc. breached their fiduciary duties to shareholders. Long-term shareholders of Charles River stock may be eligible to seek corporat...

Market News

Bearish

3 days ago

Plasmid DNA manufacturing market to grow at 18% CAGR, reaching $10.8B by 2034 driven by gene therapy demand

More News (CRL)

Law firm investigates Charles River Labs officers for possible breach of fiduciary duties to shareholders

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Plasmid DNA manufacturing market to grow at 18% CAGR, reaching $10.8B by 2034 driven by gene therapy demand

More News (CRL)

Law firm investigates Charles River Labs officers for possible breach of fiduciary duties to shareholders

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App